Last reviewed · How we verify
L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract
L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract is a Small molecule drug developed by IRCCS San Raffaele. It is currently in Phase 1 development.
At a glance
| Generic name | L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract |
|---|---|
| Sponsor | IRCCS San Raffaele |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract CI brief — competitive landscape report
- L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract updates RSS · CI watch RSS
- IRCCS San Raffaele portfolio CI
Frequently asked questions about L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract
What is L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract?
L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract is a Small molecule drug developed by IRCCS San Raffaele.
Who makes L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract?
L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract is developed by IRCCS San Raffaele (see full IRCCS San Raffaele pipeline at /company/irccs-san-raffaele).
What development phase is L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract in?
L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract is in Phase 1.
Related
- Manufacturer: IRCCS San Raffaele — full pipeline